Y is an integer of from 0 to 6 is chosen from: 0, SO₂, -CONH-, -NHCO-, -CH₂- or
R¹ is substituted or unsubstituted mono- or polycyclic saturated hetero-cyclic ring system having 1, 2 or 3 heteroatoms where said heteroatoms are independently chosen from N, O and S and said substituents are chosen from the group comprising R²; R² is C₁₋₆ alkyl, aryl C₀₋₆alkyl, hydroxy C₀₋₆alkyl, C₁₋₆ alkoxy C₀₋₆alkyl, carboxy C₀₋₆alkyl oxo, halogen, CF₃, C₀₋₄alkylamino-C₀₋₆alkyl or C₀₋₄dialkylamino-C₀₋₆alkyl; R³ is C₁₋₈ alkyl or cycloalkyl, aryl C₀₋₄alkyl, hydroxy C₀₋₄alkyl C₁₋₄alkyloxy C₀₋₄alkyl, carboxy C₀₋₄alkyl, halogen, CF₃ or hydrogen; R⁴ is hydrogen, C₁₋₆alkyl, aryl C₀₋₄alkyl or C₁₋₆alkylcarbonyloxymethyl; and R⁵ is C₁₋₆alkyl, aryl C₀₋₄alkyl or heterocycly C₀₋₄alkyl and the pharmaceutically acceptable salts thereof; are used for the manufacture of a medicament for treating osteoporosis by inhibiting the bone resorption activity of osteoclasts.
摘要:
A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.